Bioanalytical Systems, Inc. (BASi) was founded in 1974 by Purdue University chemistry professor Peter Kissinger. The company initially provided research labs with instrumentation and consumables. In 2018, BASi merged with Seventh Wave to form Inotiv. In 2021, Inotiv acquired Envigo, a leading global provider of research models and services. The acquisition of Envigo has helped Inotiv to become a one-stop shop for the life sciences industry.
To learn more about Envigo's history, including the Harlan Laboratories and Huntingdon Life Sciences merge, and other legacy acquisitions, click here.
Inotiv is a growing company with a bright future. The company is committed to continued growth and innovation. Inotiv plans to expand its product line, enter new markets, and acquire complementary businesses. Inotiv is also committed to supporting the advancement of science and to making a positive impact on the world.
Purdue University chemistry professor, Peter Kissinger, launches Bioanalytical Systems, Inc. (BASi), headquartered in West Lafayette, Indiana, as a resource for research labs.
BASi expands its service offerings with acquisition of Toxic Pathology Services (TPS) Inc., a contract research laboratory in Evansville, Indiana. BASi expands its services to provide regulated nonclinical services for pharmaceutical and biotechnology companies.
BASi and Seventh Wave combine operations to provide broader solutions and greater scientific expertise to their clients.
BASi/Seventh Wave acquire the Smithers Avanza Toxicology Services business unit, a contract research organization (CRO) located in Gaithersburg, Maryland. The acquisition includes a GLP laboratory specializing in general toxicology, vaccine safety, and developmental and reproductive toxicology (DART) studies.
BASi rebrands to become Inotiv. The company retains its products business under the name BASi Research Products.
Inotiv acquires Ft. Collins, Colorado-based PreClinical Research Services (“PCRS”), a premier provider of surgical and medical device contract research services.
Inotiv completes the acquisition of HistoTox Labs, Inc. and the acquisition by merger of Boulder, Colorado-based Bolder BioPATH, Inc. These strategic acquisitions expand Inotiv’s nonclinical pharmacology and histopathology services and augment and extend the effective range of services from early discovery through preclinical development.
Inotiv acquires key genetic toxicology assets from MilliporeSigma’s BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data, and client list.
Inotiv acquires Gateway Pharmacology Laboratories LLC, which increases Inotiv’s drug metabolism and pharmacokinetics (DMPK) technology and capability, as well as in vitro pharmacology and toxicology studies.
Inotiv acquires Plato BioPharma, Inc. (“PBI”), a Colorado-based, in vivo pharmacology research and drug discovery company specializing in cardiovascular, renal, pulmonary, and hepatic therapeutic areas.
Inotiv acquires the rabbit breeding and supply business from Robinson Services Inc. (RSI).
Inotiv acquires Integrated Laboratory Systems (ILS), Morrisville, NC, a contract research organization specializing in genetic toxicology, in vivo and in vitro toxicology, pathology, molecular biology, bioinformatics and computational toxicology services.
Inotiv acquires facilities from Orient Bio, Inc. to provide increased service levels, animal welfare, and enhanced supply chain logistics to non-human primates for drug development.
Inotiv acquires Histion, LLC, increasing histology operations into highly-specialized plastics and medical device pathology.
Inotiv acquires Protypia, Inc., an emerging protein/peptide bioanalytical company offering high-quality, targeted tissue-based protein and peptide mass spectrometry.